TP53 and neoplasm: Likewise, there was no association between CYT and BRAF, NRAS, TP53 or NF1 mutations, indicating that immune-related alterations within the tumor microenvironment, and therefore immunotherapies, are independent of the tumor’s genotype (Figure S8).